Tier 2 — strong

Quercetin ingestion does not alter cytokine changes in athletes competing in the Western States Endurance Run

David C Nieman, Dru A Henson, J Mark Davis, Charles L Dumke, Sarah J Gross, D Paul Jenkins, E Angela Murphy, Martin D Carmichael, John C Quindry, Steven R McAnulty, Lisa S McAnulty, Alan C Utter, Eugene P Mayer
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2007 27(12):1003

Bibliography

PubMed
PMID 18184041
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled ultramarathon trial
ModelHuman intervention research
Sample63 randomized runners; 39 finishers analyzed
InterventionQuercetin 1,000 mg/day or placebo
Duration3 weeks before a 160-km race
EndpointsInflammatory measures; Exercise performance or recovery

What the study showed, in plain terms

Published in 2007, this source examined exercise and recovery. Design: Randomized double-blind placebo-controlled ultramarathon trial. Sample/model: 63 randomized runners; 39 finishers analyzed. The exposure or intervention was Quercetin 1,000 mg/day or placebo. Follow-up or treatment period: 3 weeks before a 160-km race.

Quercetin did not attenuate muscle-damage markers, cytokine responses, cortisol, or leukocyte cytokine-expression changes.

Same Western States cohort as related oxidative-stress and perceived-exertion reports; those publications are not independent replications.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Exercise: Performance, Recovery and Muscle. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Quercetin did not attenuate muscle-damage markers, cytokine responses, cortisol, or leukocyte cytokine-expression changes.
  • The recorded outcome domains were Inflammatory measures; Exercise performance or recovery.
  • The result applies to the tested exposure: Quercetin 1,000 mg/day or placebo; 3 weeks before a 160-km race.

What this study can and cannot tell us

  • Same Western States cohort as related oxidative-stress and perceived-exertion reports; those publications are not independent replications.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified